Filing Flows › NeuroPace (NPCE) › R&D spending
NeuroPace (NPCE) R&D spending by quarter
NeuroPace's R&D spending was $6.9M in Q2 2026 (second quarter 2026), -4% from Q1 2026. Over the last 7 quarters it ranged from $6.0M (Q4 2024) to $7.4M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $6.9M | -4% | +0.8% |
| Q1 2026 | $7.2M | +2% | -3% |
| Q4 2025 | $7.0M | +7% | +16% |
| Q3 2025 | $6.6M | -4% | — |
| Q2 2025 | $6.8M | -8% | — |
| Q1 2025 | $7.4M | +23% | — |
| Q4 2024 | $6.0M | — | — |
Q2 2026 at a glance
NeuroPace, Q2 2026: revenue $22.8M (+17% year over year), operating margin -22.5%, net loss $6.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is NeuroPace's R&D spending?
NeuroPace's R&D spending was $6.9M in Q2 2026 (second quarter 2026), -4% from Q1 2026.
How has NeuroPace's R&D spending changed?
Over the last 7 quarters it ranged from $6.0M (Q4 2024) to $7.4M (Q1 2025).